Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B trial of MK-8189 in acute schizophrenia
2020-000094-24Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elpipodect in schizophrenia (4 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in PANSS total score at Week 6. Started Dec 2020; status: completed.
02
Drugs
elpipodect
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2020-000094-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000094-24.